Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in Parkinson's Disease

📖 Wiki Page

experiment1006 wordssynced 2026-04-02

Overview

flowchart TD experiments_metal_ion_synuclei["Experiment Design: Metal Ion-Synuclein-Mitochond"] experiments_metal_ion_synuclei["page"] experiments_metal_ion_synuclei -->|"related to"| experiments_metal_ion_synuclei style experiments_metal_ion_synuclei fill:#81c784,stroke:#333,color:#000 experiments_metal_ion_synuclei["covers"] experiments_metal_ion_synuclei -->|"related to"| experiments_metal_ion_synuclei style experiments_metal_ion_synuclei fill:#81c784,stroke:#333,color:#000 experiments_metal_ion_synuclei["Experiment"] experiments_metal_ion_synuclei -->|"related to"| experiments_metal_ion_synuclei style experiments_metal_ion_synuclei fill:#81c784,stroke:#333,color:#000 experiments_metal_ion_synuclei["Design"] experiments_metal_ion_synuclei -->|"related to"| experiments_metal_ion_synuclei style experiments_metal_ion_synuclei fill:#81c784,stroke:#333,color:#000 style experiments_metal_ion_synuclei fill:#4fc3f7,stroke:#333,color:#000

This page covers Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in Parkinson's Disease.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[ClinicalTrials.gov](https://clinicaltrials.gov/)

Experiment Overview

Title: Metal Ion-Synuclein-Mitochondria Axis Validation in Parkinson's Disease

...

Overview

Mermaid diagram (expand to render)

This page covers Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in Parkinson's Disease.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[ClinicalTrials.gov](https://clinicaltrials.gov/)

Experiment Overview

Title: Metal Ion-Synuclein-Mitochondria Axis Validation in Parkinson's Disease

Hypothesis Tested: The Metal Ion-Synuclein-Mitochondria (MISM) Axis Hypothesis - that dysregulated iron and copper homeostasis in dopaminergic [neurons](/entities/neurons) creates a convergent pathological environment promoting alpha-synuclein aggregation AND mitochondrial dysfunction through oxidative stress.

Primary Objective: Validate the causal relationship between metal ion dyshomeostasis, alpha-synuclein aggregation, and mitochondrial dysfunction in PD patient-derived models.

Secondary Objectives:

Identify optimal biomarkers for metal dysregulation in PD

Test therapeutic modulation of metal homeostasis

Characterize genotype-phenotype interactions

Study Design

Phase 1: In vitro Validation (Year 1)

1.1 Metal-Alpha-Synuclein Aggregation Assays

Model System: Recombinant alpha-synuclein protein, iPSC-derived dopaminergic neurons

Experimental Groups:

Control (no metal addition)
Fe(III) treatment (various concentrations: 1, 5, 10, 25 μM)
Cu(II) treatment (various concentrations: 0.1, 0.5, 1, 5 μM)
Fe(III) + Cu(II) combination
Iron chelator (deferoxamine) + metal
Antioxidant (N-acetylcysteine) + metal

Readouts:

ThT fluorescence kinetics (aggregation rate)
TEM imaging (fibril morphology)
SDS-PAGE/Western blot (oligomer species)
Atomic force microscopy (fibril structure)

1.2 Mitochondrial Function Assays

Model System: iPSC-derived dopaminergic neurons from PD patients and healthy controls

Treatments:

Iron overload (ferric ammonium citrate: 10, 50, 100 μM)
Copper overload (copper sulfate: 1, 5, 10 μM)
Iron chelation (deferoxamine: 50 μM)
Combination treatments

Readouts:

Seahorse XF analysis (OCR, ATP production)
MitoSOX imaging (mitochondrial ROS)
Mitochondrial membrane potential (TMRE)
Complex I-V activities
mtDNA copy number

1.3 Oxidative Stress Markers

Readouts:

8-OHdG (DNA oxidation) - immunostaining, ELISA
4-HNE (lipid peroxidation) - Western blot, mass spectrometry
Protein carbonylation - OxyBlot assay
GSH/GSSG ratio - HPLC
Catalase, SOD activities - enzymatic assays

Phase 2: Animal Validation (Year 1-2)

2.1 Mouse Model Studies

Models:

C57BL/6J wild-type + MPTP lesion
A53T alpha-synuclein transgenic mice
HFE knockout mice (iron overload model)
Cross: A53T × HFE-/-

Treatment Groups (n=15 per group):

Vehicle control

Iron chelator (deferoxamine: 50 mg/kg/day, IP)

Copper chelator (trientine: 100 mg/kg/day, IP)

Combination (deferoxamine + trientine)

Antioxidant (CoQ10: 100 mg/kg/day, oral)

Positive control: MAO-B inhibitor (selegiline)

Endpoints (12 weeks):

Behavioral: Rotarod, cylinder test, gait analysis
Histology: TH+ neuron count, iron staining (Perls), alpha-synuclein aggregation (pSer129)
Biochemistry: Mitochondrial function, oxidative stress markers
MRI: Quantitative susceptibility mapping (QSM) for iron

2.2 Mechanistic Studies

Viral Vector Approaches:

AAV-FTH1 (ferritin heavy chain) overexpression
AAV-CP (ceruloplasmin) overexpression
shRNA targeting DMT1 (divalent metal transporter)

Phase 3: Clinical Translation (Year 2-3)

3.1 Biomarker Discovery Cohort

Participants:

Early-stage PD (n=100)
Prodromal PD (n=50)
Healthy controls (n=100)

Biomarkers:

Serum: Ferritin, transferrin, ceruloplasmin, hepcidin
CSF: Iron, copper, ferritin, alpha-synuclein, oxidative stress markers
Imaging: QSM-MRI for brain iron, R2* for substantia nigra

Correlations:

Biomarker levels vs. MDS-UPDRS scores
Biomarker levels vs. disease duration
Biomarker levels vs. genetic status ([GBA](/entities/gba), [LRRK2](/entities/lrrk2), SNCA)

3.2 Pilot Clinical Trial

Design: Randomized, double-blind, placebo-controlled

Intervention:

Treatment: Deferasirox (30 mg/kg/day oral)
Duration: 12 months
Sample size: n=60 per arm

Primary Endpoint:

Change in MDS-UPDRS Part III (motor) score

Secondary Endpoints:

CSF biomarkers (iron, alpha-synuclein, oxidative stress)
QSM-MRI brain iron
Timed Up and Go test
Quality of Life (PDQ-39)

Statistical Analysis Plan

Sample Size Calculations

In vitro:

Power: 0.80, α = 0.05
Expected effect size: 30% reduction in aggregation with chelation
n = 3 replicates × 6 conditions = 18 per experiment

Animal:

Power: 0.80, α = 0.05
Expected effect: 25% improvement in behavioral scores
n = 15 per group (6 groups = 90 total)

Clinical:

Power: 0.80, α = 0.05
Expected difference: 4 points on MDS-UPDRS
n = 60 per arm (120 total)

Analysis Methods

ANOVA with Tukey post-hoc for multiple comparisons
Linear mixed models for longitudinal data
Correlation analysis (Pearson/Spearman)
Kaplan-Meier for progression analysis
Machine learning for biomarker panel optimization

Risk Assessment

Potential Risks

Iron chelation: Anemia, retinal toxicity (monitor hemoglobin, eye exams)

Animal models: Standard toxicology endpoints

Clinical trial: Iron deficiency, organ dysfunction

Mitigation Strategies

Close monitoring of iron parameters

Stopping rules for safety

Data safety monitoring board

Budget Estimate

| Phase | Item | Cost (USD) |
|-------|------|------------|
| Phase 1 | iPSC differentiation, reagents | $200,000 |
| Phase 1 | Animal studies | $300,000 |
| Phase 2 | Biomarker cohort | $150,000 |
| Phase 2 | Clinical trial (preclinical) | $500,000 |
| Phase 3 | Pilot clinical trial | $2,000,000 |
| Total | | $3,150,000 |

Timeline

| Milestone | Target Date |
|-----------|--------------|
| Phase 1 start | Month 1 |
| Phase 1 complete | Month 12 |
| Phase 2 start | Month 10 |
| Phase 2 complete | Month 36 |
| Biomarker cohort complete | Month 30 |
| Clinical trial start | Month 24 |
| Final analysis | Month 48 |

Expected Outcomes

Primary

Validation of MISM axis: Demonstrate that metal dysregulation is a primary driver of both alpha-synuclein aggregation and mitochondrial dysfunction

Biomarker panel: Identify serum/CSF biomarkers that predict PD progression

Therapeutic target: Establish metal modulation as a viable therapeutic strategy

Secondary

Mechanistic insights: Characterize iron-copper interaction in dopaminergic neurons

Genetic modifiers: Identify patients who would benefit most from metal-targeted therapy

Combination therapy: Develop optimized treatment protocols

[Metal Ion-Synuclein-Mitochondria Axis Hypothesis](/hypotheses/metal-ion-synuclein-mitochondria-axis-parkinsons)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
[Oxidative Stress](/mechanisms/oxidative-stress)

References

[Dexter DT et al., J Neurochem (1989) - Iron in Parkinson's disease (1989)](https://pubmed.ncbi.nlm.nih.gov/2565721/)

[Wang JY et al., Antioxid Redox Signal (2016) - Copper-synuclein aggregation (2016)](https://pubmed.ncbi.nlm.nih.gov/27147073/)

[Gencer M et al., Biometals (2020) - Iron and copper in PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32852102/)

Unknown, FDA Guidance: Deferoxamine clinical trials (n.d.)

Unknown, MDS-UPDRS Scale (n.d.)

📖 View canonical wiki page →

Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in Parkinson's Disease

Overview

See Also

External Links

Experiment Overview

Overview

See Also

External Links

Experiment Overview

Study Design

Phase 1: In vitro Validation (Year 1)

1.1 Metal-Alpha-Synuclein Aggregation Assays

1.2 Mitochondrial Function Assays

1.3 Oxidative Stress Markers

Phase 2: Animal Validation (Year 1-2)

2.1 Mouse Model Studies

2.2 Mechanistic Studies

Phase 3: Clinical Translation (Year 2-3)

3.1 Biomarker Discovery Cohort

3.2 Pilot Clinical Trial

Statistical Analysis Plan

Sample Size Calculations

Analysis Methods

Risk Assessment

Potential Risks

Mitigation Strategies

Budget Estimate

Timeline

Expected Outcomes

Primary

Secondary

References

Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in Parkinson's Disease

Overview

See Also

External Links

Experiment Overview

Overview

See Also

External Links

Experiment Overview

Study Design

Phase 1: In vitro Validation (Year 1)

1.1 Metal-Alpha-Synuclein Aggregation Assays

1.2 Mitochondrial Function Assays

1.3 Oxidative Stress Markers

Phase 2: Animal Validation (Year 1-2)

2.1 Mouse Model Studies

2.2 Mechanistic Studies

Phase 3: Clinical Translation (Year 2-3)

3.1 Biomarker Discovery Cohort

3.2 Pilot Clinical Trial

Statistical Analysis Plan

Sample Size Calculations

Analysis Methods

Risk Assessment

Potential Risks

Mitigation Strategies

Budget Estimate

Timeline

Expected Outcomes

Primary

Secondary

Related Pages

References